Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
The study aims to address whether the timing of stereotactic radiotherapy (SRT) after surgical removal of brain metastases impacts on quality of life; that is, whether treatment on local recurrence (disease returning at the surgical cavity) impacts on quality of life more than upfront SRT following resection of brain metastases. Who is it for? You may be eligible to participate in this study if you are aged 18 years or above and have had 1-3 brain metastases surgically removed. Study details: After surgical removal of brain metastases, in the absence of further treatment, about half of patients will develop a recurrence (disease returning) within the surgical cavity(s), while about half will not. For patients who had 1-3 brain metastases surgically removed, SRT targeting the surgical cavity(s) has been shown to provide local control rates of 70-90% at 1 year. Nevertheless, approximately 50% of patients are destined to never recur at the surgical cavity(s); hence close observation, with radiotherapy at the first sign of recurrence is also often practised. This approach spares treatment in potentially half of patients. By using regular 3-monthly MRIs of the brain, most recurrences should be detected while they are small and before symptoms develop. The study aims to address whether the timing of SRT after surgical removal of brain metastases impacts on quality of life. We are also studying the effect of treatment on patient’s neurocognitive function (memory, thinking processes). It is hypothesized that delivering SRT on local recurrence is no worse than upfront SRT to resection cavity in terms of patient’s quality of life.
Conditions
This trial is treating people with brain metastases
Eligibility
Inclusion
1 Age >/=18 years
2 Number of brain metastases – 1-4 brain metastases (as defined on the pre-operative MRI brain) and complete resection of the lesions on post-operative imaging performed within 4 weeks of surgery
3 Non-primary brain tumour site
4 ECOG performance status 0-3
5 Expected life expectancy of >6 months
6 Size of each resection cavity – resection cavity must measure < /=5.0 cm in maximal extent on the post-operative MRI obtained within 4 weeks post-surgery.
7 Tumour staging procedures – all standard tumour-staging procedures necessary to define baseline extra-cranial disease status completed < /=42 days prior to registration
8 Willing or able to complete health-related questionnaires by themselves and by a carer/proxy, if available
9 Willing and able to complete neurocognitive assessments
Exclusion
1 More than 4 untreated brain metastases
2 Prior cranial radiation therapy
3 Leptomeningeal metastases
4 Inability to complete MRI brain
5 Known allergy to gadolinium
6 Remaining unresected brain metastases
7 Planned cytotoxic chemotherapy during stereotactic radiotherapy (SRT)
8 Other tumour types – primary germ cell tumour, small cell carcinoma, or lymphoma
9 Resected cavities unsuitable for SRT (eg. located < /= 2 mm from the optic chiasm)
10 Pregnant or lactating women
11 Men or women of childbearing potential who are unwilling to employ adequate contraception throughout study
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have had a certain type of treatment or surgical procedure.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
William Buckland Radiotherapy Centre
Scientific Title
Randomised trial of adjuvant versus delayed stereotactic radiotherapy to resection cavity of brain metastases and quality of life outcomes
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information